Clinical Trials Logo

Neurocysticercosis clinical trials

View clinical trials related to Neurocysticercosis.

Filter by:

NCT ID: NCT06376396 Not yet recruiting - Neurocysticercosis Clinical Trials

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

NeuroSolve
Start date: June 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare the combination albendazole and praziquantel versus albendazole alone in patients affected by neurocysticercosis.

NCT ID: NCT05010811 Completed - Cysticercosis Clinical Trials

Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review

Start date: October 22, 2016
Phase:
Study type: Observational

Isolation lung cysticercosis reports are rare in literature. Most lung lesions were characterized by nodules. The investigators access one case which was characterized with pulmonary cavity and pleural effusion by Gupta N, et al in 2015 from PUBMED and Medline. But pleural effusion and exudative lesions is reported for the first time.

NCT ID: NCT04706819 Not yet recruiting - Neurocysticercosis Clinical Trials

Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study

Start date: January 15, 2021
Phase:
Study type: Observational [Patient Registry]

Neurocysticercosis(NCC) is the commonest parasitic infection of the central nervous system. It is the commonest cause of focal seizures in India. It can also present with headaches, movement disorders, stroke, cognitive decline and multitude of complications depending on its location. Parenchymal NCC is more common than extraparenchymal NCC. There is considerable variation in the treatment practices including administration of anti-helminthic agents and corticosteroids. Extra-parenchymal NCC is rare and can occur in the subarachnoid space or intraventricularly. Extra-parenchymal NCC is managed surgically in several instances. There is scant literature on the long term follow up of this condition. This registry will enable collection of data on the clinical, laboratory and imaging features, treatment trends and long term outcomes of both parenchymal and extra-parenchymal neurocysticercosis.

NCT ID: NCT03950037 Withdrawn - Clinical trials for Subarachnoid Neurocysticercosis

SANCC: Clinical Trial Early Intervention

Start date: January 1, 2022
Phase: Phase 2
Study type: Interventional

Subarachnoid neurocysticercosis (SANCC) is a severe infection of the brain by the tapeworm Taenia solium. People who have this infection are usually diagnosed late in the disease process leading to very poor prognosis. This trial studies the safety of early medical intervention in people who have SANCC but do not have symptoms. The trial will enroll 18 participants in Peru.

NCT ID: NCT03874689 Completed - Neurocysticercosis Clinical Trials

Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia

TEPIM
Start date: June 1, 2019
Phase:
Study type: Observational

This study aims to determine the prevalence of taeniosis and (neuro)cysticercosis in two districts in the southern (Gwembe) and eastern province (Chipata) of Zambia.

NCT ID: NCT03851419 Completed - HIV/AIDS Clinical Trials

The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania

CYSTINET_Tz
Start date: April 1, 2018
Phase:
Study type: Observational

This study aims to compare the burden of neurocysticercosis among people living with HIV to people not infected with HIV.

NCT ID: NCT03834337 Completed - Neurocysticercosis Clinical Trials

Treatment of Patients With Active Neurocysticercosis in Eastern Africa

TOPANA
Start date: April 1, 2019
Phase:
Study type: Observational

This multi-centre prospective cohort study of symptomatic patients with active neurocysticercosis (NCC) aims to identify factors related to treatment success of anthelmintic therapy. Neurological symptom/sign and cyst resolution, quality of life, accuracy and performance of serological T. solium diagnostics and NCC-specific immunological parameter will be followed up at multiple time points in the study. The final assessment will be done six months after the end of anthelmintic treatment. This study aims to guide treatment of NCC in sub-Saharan Africa by identifying factors that are associated with treatment outcomes. The factors that cause some people to fail complete resolution of all cysts and/or symptoms/signs are unknown.

NCT ID: NCT03808597 Completed - HIV Infections Clinical Trials

Digital Health Promotion in Iringa, Tanzania

Start date: April 1, 2019
Phase: N/A
Study type: Interventional

Increased health education has the potential to facilitate better use of health care services and to promote early treatment, thus it can strengthen the health care system, and ultimately reduce morbidity and mortality. In this study, we will develop and test the effect of digital health messages related to HIV, Tuberculosis (TB) and Taenia solium cysticercosis/taeniosis (TSCT) (the intervention diseases) in Migoli and Izazi (the intervention villages), in Iringa, Tanzania (TZ). The intervention is planned as follows: A digital platform, providing the intervention villages with digital health messages related to the above-mentioned diseases, will be implemented in TZ in 2019. The platform will be accessible free of charge, through own devices and tablets based in the local Wi-Fi spots in the villages. In the first part of this project, the doctoral research fellow will participate in developing the digital health messages, together with experts from the medical and teaching environments in Tanzania, Norway, Germany and USA. The second part of the PhD-project consists of a cluster non-randomised controlled trial and semi-structured interviews in Tanzania. The digital health messages will be physically shown to the participants in the intervention group. The study is planned to investigate the knowledge related to the intervention diseases, before the intervention, immediately after exposure to the intervention, and at follow-up points throughout one year, after the intervention has been implemented. Semi-structured interviews with clients (users of the intervention) from each of the intervention villages are included, to explore the perception and reception of the intervention. The baseline study and the immediate after survey will take place in Tanzania in Q1 2019, while the other follow-up studies and interviews (3, 6 and 12 months after baseline) will be undertaken throughout one year.

NCT ID: NCT03095339 Completed - Cysticercosis Clinical Trials

EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso

EFECAB
Start date: February 21, 2011
Phase: N/A
Study type: Interventional

This is a pre-post randomized community-based controlled trial aimed at estimating the effectiveness of an educational package developed using PRECEDE PROCEED to reduce the cumulative incidence of Taenia solium cysticercosis in three Provinces of Burkina Faso. The study design included an 18-months baseline study to measure baseline cumulative incidence of cysticercosis followed by an 18-month post randomization study to measure the effectiveness of the intervention. Sixty villages of three Provinces of Burkina Faso were included. The primary outcome was the change in the baseline to post randomization cumulative incidence in the intervention group compared to the control group.

NCT ID: NCT02947581 Terminated - Neurocysticercosis Clinical Trials

Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)

SANTO
Start date: November 14, 2016
Phase: Phase 3
Study type: Interventional

Taenia solium neurocysticercosis (NCC) is a parasitic infection causing much neurological disease in most of the world. When parasites locate in the cavities around the brain (subarachnoid NCC, SANCC), it becomes an aggressive, progressive and frequently lethal presentation. Current treatment regimens for SANCC have quite limited efficacy. The investigators propose to compare the current standard of care (a single antiparasitic drug, albendazole) with a combined regimen using two antiparasitic drugs simultaneously by adding praziquantel. The trial will enrol 164 patients in four centers, two in Peru, one in Ecuador, and one in Brasil.